363 related articles for article (PubMed ID: 23246628)
1. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
2. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
[TBL] [Abstract][Full Text] [Related]
3. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
[TBL] [Abstract][Full Text] [Related]
4. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.
Cataldi M; Shah NR; Felt SA; Grdzelishvili VZ
Virology; 2015 Nov; 485():340-54. PubMed ID: 26331681
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
6. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
7. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
8. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
9. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
10. Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.
Malilas W; Koh SS; Srisuttee R; Boonying W; Cho IR; Jeong CS; Johnston RN; Chung YH
Cancer Gene Ther; 2013 Feb; 20(2):125-32. PubMed ID: 23306614
[TBL] [Abstract][Full Text] [Related]
11. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
Felt SA; Droby GN; Grdzelishvili VZ
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
[TBL] [Abstract][Full Text] [Related]
14. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
15. MxA Mediates SUMO-Induced Resistance to Vesicular Stomatitis Virus.
Maarifi G; Hannoun Z; Geoffroy MC; El Asmi F; Zarrouk K; Nisole S; Blondel D; Chelbi-Alix MK
J Virol; 2016 Jul; 90(14):6598-6610. PubMed ID: 27170750
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
18. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
Escobar-Zarate D; Liu YP; Suksanpaisan L; Russell SJ; Peng KW
Cancer Gene Ther; 2013 Oct; 20(10):582-9. PubMed ID: 24030211
[TBL] [Abstract][Full Text] [Related]
19. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.
Olagnier D; Lababidi RR; Hadj SB; Sze A; Liu Y; Naidu SD; Ferrari M; Jiang Y; Chiang C; Beljanski V; Goulet ML; Knatko EV; Dinkova-Kostova AT; Hiscott J; Lin R
Mol Ther; 2017 Aug; 25(8):1900-1916. PubMed ID: 28527723
[TBL] [Abstract][Full Text] [Related]
20. Impaired antiviral response in human hepatoma cells.
Keskinen P; Nyqvist M; Sareneva T; Pirhonen J; Melén K; Julkunen I
Virology; 1999 Oct; 263(2):364-75. PubMed ID: 10544109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
